Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $9.4 million.

  • InMed Pharmaceuticals' Cash & Equivalents rose 6836.71% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 6836.71%. This contributed to the annual value of $11.1 million for FY2025, which is 6854.12% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Cash & Equivalents is $9.4 million, which was up 6836.71% from $11.1 million recorded in Q2 2025.
  • InMed Pharmaceuticals' Cash & Equivalents' 5-year high stood at $15.3 million during Q3 2021, with a 5-year trough of $3.5 million in Q4 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $8.9 million (2023), whereas its average is $8.4 million.
  • In the last 5 years, InMed Pharmaceuticals' Cash & Equivalents crashed by 6329.28% in 2024 and then skyrocketed by 6854.12% in 2025.
  • InMed Pharmaceuticals' Cash & Equivalents (Quarter) stood at $11.3 million in 2021, then rose by 1.53% to $11.5 million in 2022, then decreased by 16.74% to $9.5 million in 2023, then plummeted by 63.29% to $3.5 million in 2024, then soared by 168.57% to $9.4 million in 2025.
  • Its Cash & Equivalents was $9.4 million in Q3 2025, compared to $11.1 million in Q2 2025 and $4.7 million in Q1 2025.